A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Clinical trial NCT06525220 · RECRUITING

Trial details

NCT number: NCT06525220
Sponsor: Merus B.V.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma

Start date: 2024-09-25
Primary completion: 2028-01-01
Enrollment: 700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.